Cancer Conditions & Treatments

We now know that cancer is a genetic disease, and that accumulation of molecular alterations in the genome is the basis of cancer initiation and progression. In the past ten years, the availability of the human genome sequence and progress and DNA sequencing has dramatically improved the knowledge and treatment of cancer. Personalized cancer testing and treatment are unique and personalized to each patient.

We are now able to measure circulating cancer cells in your blood. A count of circulating tumor cells present in the bloodstream is indicative of tumor burden and tumor spread. These tumor DNA cells can predict remission and prognosis and are valuable to assess the aggressiveness of your tumor. Evaluation of the cells allows for the early detection and diagnosis of new cancers as well as the monitoring of existing Cancers

Types of Cancer We Treat

Brain Cancer

The cancer genome atlas research network has provided new insights into the personalized genomics mutations that drive disease

Breast Cancer

World wide breast cancer is the most frequently diagnosed cancer and the leading cause of death among females. Measure your ne

Colon Cancer

Measure your genomic “driver mutations” and block these critical pathways using targeted low-dose targeted chemotherapy 

Kidney Cancer

It is anticipated that in the future kidney cancer will soon become a chronic disorder as we understand the cancer genome. 


Lung Cancer

Lung cancer is the leading cause of cancer-related deaths in the United States. Non-small cell lung cancer represents 80%, 


For Hodgkin lymphoma and non-Hodgkin’s lymphoma, new testing allows us to target cancer mutations using low-dose chemotherapy, 


The genetic and molecular understanding of melanoma is transforming its treatment. Measure your molecular mutational drivers 


Ovarian Cancer

Gynecological cancer research is changing the way we treat ovarian cancer. We can now measure the molecular pathways and block these



Pancreatic Cancer

We can now offer patients promising new therapies based on the new revolutionary genome at testing. By evaluating your cancer biomarkers, 


Uterine Cancer

Endometrial cancer is the most common gynecologic malignancy. With new genomic biomarkers, we can develop personalized programs,


Other Cancer

Please call us for an in-depth discussion of your cancer and the treatment modalities from around the world available here